Exchange: NASDAQ·Updated 07:54 PM EDT
News
all
press releases
Kura Oncology (KURA) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
More News
Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy?
Does Kura Oncology (KURA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
The Catalyst Explosion: Insider Buying, Phase 3 Wins, Bitcoin Billions and Shorts Under Pressure
The market is serving up a explosive mix of catalysts for listings like NeOnc Technologies Holdings (NASDAQ:NTHI), Wetour Robotics (NASDAQ:WETO), Kura Oncology (NASDAQ:KURA), Amylyx Pharmaceuticals (NASDAQ:AMLX), EyePoint Pharmaceuticals (NASDAQ:EYPT), and Super League Enterprise (NASDAQ:SLE).
24-7 Market News
Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect?
The mean of analysts' price targets for Kura Oncology (KURA) points to a 178.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Why Is KURA Stock Rallying 8% After-Hours?
According to a filing with the Securities and Exchange Commission, President and CEO Wilson bought 100,000 shares at an average price of $11.12.
Stocktwits
Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates
Kura Oncology (KURA) delivered earnings and revenue surprises of +13.48% and +23.61%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +21.74% and +10.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of -17.65% and -3.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of -120.00% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates
Cognition Therapeutics (CGTX) delivered earnings and revenue surprises of +33.33% and -120.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.